Autonomix Medical, Inc.

Autonomix Medical, Inc. reported its financial position as of July 28, 2026. The company's cash balance stood at approximately $5.1 million. Additionally, the total number of common shares outstanding was 971,043, which includes shares issued as part of a recent warrant inducement completed on July 13, 2026.

Autonomix Medical, Inc. announced positive results from a preclinical study for its proprietary neural sensing platform. The study successfully demonstrated the platform's ability to detect, localize, and confirm changes in renal neural activity, providing direct physiological feedback before and after targeted ablation. These findings represent a critical milestone, supporting the continued development of the platform for physiology-guided renal denervation procedures, which currently lack direct physiological feedback. The company plans further preclinical and clinical studies.

Autonomix Medical, Inc. announced the issuance of U.S. Patent No. 12,471,776, titled "ANS Assessment Systems, Kits, and Methods." This patent significantly strengthens the company's intellectual property portfolio for its proprietary autonomic nervous system technologies. The patent broadly covers systems and methods for monitoring physiologic signals to assess ANS activity, including technologies for patient selection, procedural guidance, and post-treatment monitoring across neuromodulation applications. CEO Brad Hauser stated that this innovation reinforces their vision of building a differentiated technology platform for precision nerve-targeted treatments.

Autonomix Medical, Inc. announced a warrant inducement offer, securing approximately $2.6 million in gross proceeds. The company reduced the exercise price of existing Series C warrants to $6.00 per share, prompting the holder to exercise 428,731 shares. In consideration, Autonomix issued new Series D-1 and D-2 unregistered warrants, each for 428,731 shares, with an exercise price of $5.75 per share and a 5.5-year term. Maxim Group LLC acted as the warrant solicitation agent.

Autonomix Medical, Inc. announced the issuance of U.S. Patent No. 12,611,134, titled "Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder." This patent significantly expands the company's proprietary neural sensing and therapeutic technology into the large urology market, targeting a condition that affects approximately 37 million Americans. The new patent reinforces Autonomix's strategy of developing organ-specific applications from its scalable core technology and brings its total intellectual property portfolio to 112 issued or pending patent applications globally.

Autonomix Medical, Inc. announced a warrant inducement agreement with an investor for the immediate exercise of outstanding November 2025 Warrants. This transaction is expected to generate approximately $2.6 million in gross proceeds for the company. In consideration, Autonomix will issue new Series D-1 and Series D-2 warrants to the investor, each exercisable at $5.75 per share.

Autonomix Medical, Inc. announced it has been granted Canadian Patent No. 3,158,197, titled "Endoscopic Sympathectomy Systems and Methods." This new patent strengthens the company's intellectual property position in nerve-targeted therapies and denervation applications, bringing its global IP portfolio to 112 issued or pending patent applications. The patented technology focuses on real-time nerve monitoring, diagnostic evaluation, and feedback-guided neuromodulation for precise targeting of autonomic nerves in chronic disease states, reinforcing Autonomix's competitive edge in major commercial markets.

Autonomix Medical, Inc. announced it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement. The company previously received a deficiency letter on January 14, 2026, for its common stock trading below $1.00 per share. On July 9, 2026, Nasdaq confirmed that Autonomix Medical had met the Bid Price Rule by maintaining a closing bid price of $1.00 or more for 10 consecutive business days, from June 24, 2026, through July 8, 2026.

Autonomix Medical, Inc. announced an amendment to its certificate of incorporation to effect a 1-for-21 reverse stock split of its common stock. The split will become effective at 12:01 am ET on June 24, 2026, with post-split trading commencing the same day on The Nasdaq Capital Market under the existing ticker "AMIX" but with a new CUSIP number. This action will reduce the number of outstanding shares from approximately 11.4 million to about 543,000, while the authorized shares remain at 500 million.

Autonomix Medical, Inc. (AMIX) has filed an amendment to its 2026 Form 10-K to include Part III information, covering directors, executive officers, and corporate governance. The filing details executive compensation for fiscal years 2026 and 2025, with salaries for Brad Hauser, Lori Bisson, and Trent Smith disclosed. The company also outlined the responsibilities and composition of its Audit, Compensation, and Nominating and Governance committees.